Clinical Trial: A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma

U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06841185) titled 'A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma' on Feb. 18.

Brief Summary: This is a multicenter, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the efficacy, safety, PK, and immunogenicity of HLX13 and YERVOY(R) in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: Hepatocellular Carcinoma (HCC)

Intervention: DRUG: HLX13

HLX13 (...